Sequential high-intensity focused ultrasound treatment combined with chemotherapy for inoperable pancreatic cancer: a retrospective analysis for prognostic factors and survival outcomes

Reference

• Gupta R, Amanam I, Chung V. Current and future therapies for advanced pancreatic cancer. J Surg Oncol. 2017;116(1):25–34. doi: 10.1002/jso.24623.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi: 10.3322/caac.21654.
   PubMed Web of Science ®Google Scholar
• Hatashima A, Arango MJ, Reardon J, et al. First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population. Future Oncol. 2022;18(20):2521–2532. doi: 10.2217/fon-2021-1367.
   PubMed Web of Science ®Google Scholar
• Goral V. Pancreatic cancer: pathogenesis and diagnosis. Asian Pac J Cancer Prev. 2015;16(14):5619–5624. doi: 10.7314/apjcp.2015.16.14.5619.
   PubMedGoogle Scholar
• Adamska A, Domenichini A, Falasca M. Pancreatic ductal adenocarcinoma: current and evolving therapies. Int J Mol Sci. 2017;18(7):1338. doi: 10.3390/ijms18071338.
   PubMed Web of Science ®Google Scholar
• Ning Z, Xie J, Chen Q, et al. HIFU is safe, effective, and feasible in pancreatic cancer patients: a monocentric retrospective study among 523 patients. Onco Targets Ther. 2019;12:1021–1029. doi: 10.2147/OTT.S185424.
   PubMed Web of Science ®Google Scholar
• Wang K, Chen L, Meng Z, et al. High intensity focused ultrasound treatment for patients with advanced pancreatic cancer: a preliminary dosimetric analysis. Int J Hyperthermia. 2012;28(7):645–652. doi: 10.3109/02656736.2012.713541.
   PubMed Web of Science ®Google Scholar
• Marinova M, Wilhelm-Buchstab T, Strunk H. Advanced pancreatic cancer: high-Intensity focused ultrasound (HIFU) and other local ablative therapies. Rofo. 2019;191(3):216–227. doi: 10.1055/a-0820-5564.
   PubMedGoogle Scholar
• Marinova M, Huxold HC, Henseler J, et al. Clinical effectiveness and potential survival benefit of US-guided high-intensity focused ultrasound therapy in patients with advanced-stage pancreatic cancer. Ultraschall Med. 2019;40(5):625–637. doi: 10.1055/a-0591-3386.
   PubMed Web of Science ®Google Scholar
• Thudium M, Bette B, Tonguc T, et al. Multidisciplinary management and outcome in pancreatic cancer patients treated with high-intensity focused ultrasound. Int J Hyperthermia. 2020;37(1):456–462. doi: 10.1080/02656736.2020.1762006.
   PubMed Web of Science ®Google Scholar
• Tao SF, Gu WH, Gu JC, et al. A retrospective case series of high-intensity focused ultrasound (HIFU) in combination with gemcitabine and oxaliplatin (gemox) on treating elderly middle and advanced pancreatic cancer. Onco Targets Ther. 2019;12:9735–9745. doi: 10.2147/OTT.S220299.
   PubMed Web of Science ®Google Scholar
• Dell’Aquila E, Fulgenzi CAM, Minelli A, et al. Prognostic and predictive factors in pancreatic cancer. Oncotarget. 2020;11(10):924–941. doi: 10.18632/oncotarget.27518.
   PubMedGoogle Scholar
• Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol. 2012;3(2):105–119.
   PubMedGoogle Scholar
• Luchini C, Brosens LAA, Wood LD, et al. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. Gut. 2021;70(1):148–156. doi: 10.1136/gutjnl-2020-320726.
   PubMed Web of Science ®Google Scholar
• Ning ZY, Cheng CS, Xie J, et al. A retrospective analysis of survival factors of high intensity focused ultrasound (HIFU) treatment for unresectable pancreatic cancer. Discov Med. 2016;21(118):435–445.
   PubMed Web of Science ®Google Scholar
• Ishido K, Hakamada K, Kimura N, et al. Essential updates 2018/2019: current topics in the surgical treatment of pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg. 2021;5(1):7–23. doi: 10.1002/ags3.12379.
   PubMed Web of Science ®Google Scholar
• Satoi S. Surgical treatment of pancreatic ductal adenocarcinoma. Cancers (Basel). 2021;13(16):4015. doi: 10.3390/cancers13164015.
   PubMed Web of Science ®Google Scholar
• Friedl J, Turner E, Alexander HR. Jr. Augmentation of endothelial cell monolayer permeability by hyperthermia but not tumor necrosis factor: evidence for disruption of vascular integrity via VE-cadherin down-regulation. Int J Oncol. 2003;23(3):611–616.
   PubMed Web of Science ®Google Scholar
• Issels RD. Regional hyperthermia in high-risk soft tissue sarcomas. Curr Opin Oncol. 2008;20(4):438–443. doi: 10.1097/CCO.0b013e3283025e50.
   PubMed Web of Science ®Google Scholar
• Salmiheimo A, Mustonen H, Stenman UH, et al. Systemic inflammatory response and elevated tumour markers predict worse survival in resectable pancreatic ductal adenocarcinoma. PLoS One. 2016;11(9):e0163064. doi: 10.1371/journal.pone.0163064.
   PubMed Web of Science ®Google Scholar
• Takahashi R, Macchini M, Sunagawa M, et al. Interleukin-1beta-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression. Gut. 2021;70(2):330–341.
   PubMed Web of Science ®Google Scholar
• Marinova M, Rauch M, Mucke M, et al. High-intensity focused ultrasound (HIFU) for pancreatic carcinoma: evaluation of feasibility, reduction of tumour volume and pain intensity. Eur Radiol. 2016;26(11):4047–4056. doi: 10.1007/s00330-016-4239-0.
   PubMed Web of Science ®Google Scholar
• Strunk HM, Lutzow C, Henseler J, et al. Mesenteric vessel patency following HIFU therapy in patients with locally invasive pancreatic cancer. Ultraschall Med. 2018;39(6):650–658. doi: 10.1055/s-0043-125391.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Shen H, Hu XY, et al. Multidisciplinary treatment with chemotherapy, targeted drug, and high-intensity focused ultrasound in advanced pancreatic carcinoma. Med Oncol. 2012;29(2):957–961. doi: 10.1007/s12032-011-9892-1.
   PubMed Web of Science ®Google Scholar
• Zhong A, Cheng CS, Kai J, et al. Clinical significance of glucose to lymphocyte ratio (GLR) as a prognostic marker for patients with pancreatic cancer. Front Oncol. 2020;10:520330. doi: 10.3389/fonc.2020.520330.
   PubMed Web of Science ®Google Scholar
• Singhi AD, Koay EJ, Chari ST, et al. Early detection of pancreatic cancer: opportunities and challenges. Gastroenterology. 2019;156(7):2024–2040. doi: 10.1053/j.gastro.2019.01.259.
   PubMed Web of Science ®Google Scholar
• Guo M, Luo G, Lu R, et al. Distribution of lewis and secretor polymorphisms and corresponding CA19-9 antigen expression in a Chinese population. FEBS Open Bio. 2017;7(11):1660–1671. doi: 10.1002/2211-5463.12278.
   PubMed Web of Science ®Google Scholar
• Jiang K, Tan E, Sayegh Z, et al. Cancer antigen 125 (CA125, MUC16) protein expression in the diagnosis and progression of pancreatic ductal adenocarcinoma. Appl Immunohistochem Mol Morphol. 2017;25(9):620–623. doi: 10.1097/PAI.0000000000000368.
   PubMedGoogle Scholar
• Luo G, Liu C, Guo M, et al. Potential biomarkers in lewis negative patients with pancreatic cancer. Ann Surg. 2017;265(4):800–805. doi: 10.1097/SLA.0000000000001741.
   PubMed Web of Science ®Google Scholar
• Luo G, Xiao Z, Long J, et al. CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer. J Gastrointest Surg. 2013;17(12):2092–2098. doi: 10.1007/s11605-013-2389-9.
   PubMed Web of Science ®Google Scholar
• Balachandran VP, Łuksza M, Zhao JN, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017;551(7681):512–516. doi: 10.1038/nature24462.
   PubMed Web of Science ®Google Scholar
• Farrow B, Sugiyama Y, Chen A, et al. Inflammatory mechanisms contributing to pancreatic cancer development. Ann Surg. 2004;239(6):763–771. doi: 10.1097/01.sla.0000128681.76786.07.
   PubMed Web of Science ®Google Scholar
• Elinav E, Nowarski R, Thaiss CA, et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13(11):759–771. doi: 10.1038/nrc3611.
   PubMed Web of Science ®Google Scholar
• Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nat Rev Clin Oncol. 2020;17(9):527–540. doi: 10.1038/s41571-020-0363-5.
   PubMed Web of Science ®Google Scholar
• Ren B, Cui M, Yang G, et al. Tumor microenvironment participates in metastasis of pancreatic cancer. Mol Cancer. 2018;17(1):108. doi: 10.1186/s12943-018-0858-1.
   PubMed Web of Science ®Google Scholar
• Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35–S50. doi: 10.1053/j.gastro.2004.09.014.
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009;15(2):425–430. doi: 10.1158/1078-0432.CCR-08-0149.
   PubMed Web of Science ®Google Scholar
• Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805–1812. doi: 10.1172/JCI200318921.
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Bajwa HS, Menon K, et al. Comparison between 22G aspiration and 22G biopsy needles for EUS-guided sampling of pancreatic lesions: a meta-analysis. Endosc Ultrasound. 2020;9(3):167–174. doi: 10.4103/eus.eus_4_19.
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Kovacevic B, Yang D, et al. Predictors of adverse events after endoscopic ultrasound-guided through-the-needle biopsy of pancreatic cysts: a recursive partitioning analysis. Endoscopy. 2022;54(12):1158–1168. doi: 10.1055/a-1831-5385.
   PubMed Web of Science ®Google Scholar
• Lisotti A, Napoleon B, Facciorusso A, et al. Contrast-enhanced EUS for the characterization of mural nodules within pancreatic cystic neoplasms: systematic review and meta-analysis. Gastrointest Endosc. 2021;94(5):881–889.e5. doi: 10.1016/j.gie.2021.06.028.
   PubMed Web of Science ®Google Scholar